InvestorLens

DRUG — BRIGHT MINDS BIOSCIENCES INC

Public company

Sign in to save4 tracked investors reported this
For educational research only.InvestorLens analyzes public regulatory filings (SEC EDGAR, STOCK Act PTRs) that may be delayed by 45 days or more. Information shown is historical and is not financial, legal, or tax advice, nor a recommendation or solicitation to buy or sell any security. Always do your own research.

InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.

Sourced from SEC EDGAR public filings

Why are billionaires buying DRUG?

Built from public SEC filings and public economic data. Not a recommendation.

Confidence
95
Institutional Conviction
Net accumulation · 4 buying vs 0 selling last quarter
72
Macro Tailwind
Macro conditions are mixed for this sector
55
Why? — Evidence & Confidence ▾

Of 4 tracked investors who changed their DRUG position last quarter, 4 bought and 0 sold (100% buy-side). Macro conditions are mixed for this sector (Macro Tailwind 55/100 in a Contraction regime).

Supporting evidence
  • +4 tracked investors added or increased positions last quarter (Ken Griffin, Steve Cohen, Paul Tudor Jones, …)
  • +4 tracked investors reported holding DRUG at their latest filing
  • +Macro Health is 55/100 in a Contraction regime — historically acceptable for this sectorsource
Contradicting evidence — always shown
  • −13F data is disclosed up to 45 days after quarter end — positions may have changed since
Know the limits
  • · 13F disclosure lag (up to 45 days)
  • · Tracked investors are a sample, not the whole market
  • · Sector regime fit is a historical average, not a guarantee

Every InvestorLens score shows its evidence — including what argues against it. Model conviction-v1 · generated 9/17/2026.

About BRIGHT MINDS BIOSCIENCES INC (DRUG)

BRIGHT MINDS BIOSCIENCES INC (DRUG) appears in the most recent 13F filings of 4 tracked institutional investors. The largest disclosed position is held by Steve Cohen (Point72 Asset Management), valued at $23M. Across recent filings, tracked investors recorded 6 new positions, 3 increased, 4 reduced, and 2 exited. All data sourced from SEC 13F filings.

Smart Money Consensus™

Based on recent institutional activity in DRUG

60
/100
Institutional Accumulation
Added / Increased9
Reduced4
Exited2
BearishBullish
Crowded Trade Score™

How many top investors track DRUG

27
/100
Emerging Interest
4investors

A small number of top investors own this.

UndiscoveredCrowded
151015+

DRUG Ownership Composition

How BRIGHT MINDS BIOSCIENCES INC is held across tracked investor types, based on reported 13F positions.

Dominant Type
Multi-Strategy / Quant
98% of tracked value
Institutions
4
tracked investors
Total Reported
$32.9M
combined 13F value
Types2
  • Multi-Strategy / Quant98.2%
  • Macro1.8%
Multi-Strategy / Quant(3)
98.2%
Macro(1)
1.8%

Tracked investors currently reporting DRUG

  • Steve CohenJun 30, 2026
    Point72 Asset Management
    Shares
    327.4K
    Value
    $23M
    % Portfolio
    0.03%
  • Izzy EnglanderJun 30, 2026
    Millennium Management
    Shares
    66.7K
    Value
    $4.7M
    % Portfolio
    0.00%
  • Ken GriffinJun 30, 2026
    Citadel Advisors
    Shares
    66.5K
    Value
    $4.7M
    % Portfolio
    0.00%
  • Paul Tudor JonesJun 30, 2026
    Tudor Investment Corp
    Shares
    8.3K
    Value
    $582K
    % Portfolio
    0.00%

Recent activity

Frequently asked questions

How many institutional investors hold DRUG?
4 tracked institutional investors disclosed a position in DRUG (BRIGHT MINDS BIOSCIENCES INC) in their most recent 13F filing.
Who is the largest institutional holder of DRUG?
Steve Cohen, Point72 Asset Management, holds the largest disclosed position in DRUG, valued at $23M.
Did institutional ownership of DRUG increase or decrease?
Across recent 13F filings, tracked investors recorded 6 new positions, 3 increased, 4 reduced, and 2 fully exited DRUG.
Where does this DRUG ownership data come from?
SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.